Hideaki Ogiwara

Dr. Hideaki Ogiwara


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TKTakashi Kohno
Takashi Kohno
HIHitoshi Ichikawa
Hitoshi Ichikawa
YTYasushi Totoki
Yasushi Totoki
KYKazuki Yasuda
Kazuki Yasuda
MHMasaki Hiramoto
Masaki Hiramoto
TSTatsuhiro Shibata
Tatsuhiro Shibata

10 January 2011 in Oncogene
Verified
Journal Article
Closed access
PDF file
HOHideaki Ogiwara
Hideaki Ogiwara
AUA Ui
A Ui
AOA Otsuka
A Otsuka
HSH Satoh
H Satoh
IYI Yokomi
I Yokomi
TKT Kohno
T Kohno

1 September 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
TOTakahiro Oike
Takahiro Oike
HOHideaki Ogiwara
Hideaki Ogiwara
YTYuichi Tominaga
Yuichi Tominaga
KIKentaro Ito
Kentaro Ito
OAOsamu Ando
Osamu Ando
TKTakashi Kohno
Takashi Kohno
The occurrence of inactivating mutations in SWI/SNF chromatin-remodeling genes in common cancers has attracted a great deal of interest. However, mechanistic strategies to target tumor cells carrying such mutations are yet to be developed. This study proposes a synthetic-lethality therapy for treating cancers deficient in the SWI/SNF catalytic (ATPase) subunit, BRG1/SMARCA4. The strategy relies upon inhibition of BRM/SMARCA2, another catalytic SWI/SNF subunit with a BRG1-related activity. Immunohistochemical analysis of a cohort of non–small-cell lung carcinomas (NSCLC) indicated that 15.5% (16 of 103) of the cohort, corresponding to preferentially undifferentiated tumors, was deficient in BRG1 expression. All BRG1-deficient cases were negative for alterations in known therapeutic target genes, for example, EGFR and DDR2 gene mutations, ALK gene fusions, or FGFR1 gene amplifications. RNA interference (RNAi)–mediated silencing of BRM suppressed the growth of BRG1-deficient cancer cells relative to BRG1-proficient cancer cells, inducing senescence via activation of p21/CDKN1A. This growth suppression was reversed by transduction of wild-type but not ATPase-deficient BRG1. In support of these in vitro results, a conditional RNAi study conducted in vivo revealed that BRM depletion suppressed the growth of BRG1-deficient tumor xenografts. Our results offer a rationale to develop BRM-ATPase inhibitors as a strategy to treat BRG1/SMARCA4–deficient cancers, including NSCLCs that lack mutations in presently known therapeutic target genes. Cancer Res; 73(17); 5508–18. ©2013 AACR.

1 February 2019 in Cancer Cell
Verified
Journal Article
Closed access
HOHideaki Ogiwara
Hideaki Ogiwara
KTKazuaki Takahashi
Kazuaki Takahashi
MSMariko Sasaki
Mariko Sasaki
TKTakafumi Kuroda
Takafumi Kuroda
HYHiroshi Yoshida
Hiroshi Yoshida
TKTakashi Kohno
Takashi Kohno

1 December 2010 in Molecular Cell
Verified
Journal Article
Closed access
LLLi Lan
Li Lan
AUAyako Ui
Ayako Ui
SNSatoshi Nakajima
Satoshi Nakajima
KHKotomi Hatakeyama
Kotomi Hatakeyama
MHMikiko Hoshi
Mikiko Hoshi
AYAkira Yasui
Akira Yasui

12 June 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TNTakashi Nakaoku
Takashi Nakaoku
KTKoji Tsuta
Koji Tsuta
HIHitoshi Ichikawa
Hitoshi Ichikawa
KSKouya Shiraishi
Kouya Shiraishi
HSHiromi Sakamoto
Hiromi Sakamoto
TKTakashi Kohno
Takashi Kohno
Purpose: To identify druggable oncogenic fusions in invasive mucinous adenocarcinoma (IMA) of the lung, a malignant type of lung adenocarcinoma in which KRAS mutations frequently occur. Experimental Design: From an IMA cohort of 90 cases, consisting of 56 cases (62%) with KRAS mutations and 34 cases without (38%), we conducted whole-transcriptome sequencing of 32 IMAs, including 27 cases without KRAS mutations. We used the sequencing data to identify gene fusions, and then performed functional analyses of the fusion gene products. Results: We identified oncogenic fusions that occurred mutually exclusively with KRAS mutations: CD74-NRG1, SLC3A2-NRG1, EZR-ERBB4, TRIM24-BRAF, and KIAA1468-RET. NRG1 fusions were present in 17.6% (6/34) of KRAS-negative IMAs. The CD74-NRG1 fusion activated HER2:HER3 signaling, whereas the EZR-ERBB4 and TRIM24-BRAF fusions constitutively activated the ERBB4 and BRAF kinases, respectively. Signaling pathway activation and fusion-induced anchorage-independent growth/tumorigenicity of NIH3T3 cells expressing these fusions were suppressed by tyrosine kinase inhibitors approved for clinical use. Conclusions: Oncogenic fusions act as driver mutations in IMAs without KRAS mutations, and thus represent promising therapeutic targets for the treatment of such IMAs. Clin Cancer Res; 20(12); 3087–93. ©2014 AACR.